Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
PROFIL Dr. med. Sylke Schneider-Burrus Chefärztin Zentrum für Dermatochirurgie Dr. med. Sylke Schneider-Burrus wurde am 04.05.1973 in Hückeswagen, Nordrhein-Westfalen geboren. Sie ist verheiratet und hat zwei Kinder. AKTUELLE POSITION Seit 01/2017 Chefärztin im Zentrum für Dermatochirurgie, Havelklinik Berlin Seit 01/2009 Wissenschaftliche Mitarbeiterin Charité Universitätsmedizin, Leitung des klinischen Forschungsbereichs Acne inversa Principal investigator klinischer Studien im Bereich Acne inversa BERUFLICHER WERDEGANG 07/2012 – 12/2016 Leitung der Dermatochirurgie in der Klinik für Dermatologie, Venerologie und Allergologie, Charité Universitätsmedizin. 08/2013 Anerkennung der Zusatzbezeichnung Phlebologie, Ärztekammer Berlin Promotionsarbeit 10/2000 Promotion im Fach Medizin an der Universität zu Köln. Note: Magna cum laude. Studium 05/1999 Abschluss des Studiums der Medizin mit dem dritten Staatsexamen, Gesamtnote: sehr gut. 1992 – 1999 Studium der Medizin an der Universität zu Köln. Auslandsaufenthalt 09/2001 - 09/2003 Postdoctoral Research Fellow im Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, USA. Principal Investigator: Professor Dr. Peter V. Danenberg. und Allergologie, Charité Universitätsmedizin. Titel des Projektes: Development of tailored cancer treatment. Investigation of mRNA-expression levels of tumor related genes and their relationship to clinical response to treatment. 11/2008 Kontakt 01/2009 Ernennung zur Oberärztin in der Klinik für Dermatologie, Venerologie Anerkennung als Fachärztin für Dermatologie und Venerologie, Ärztekammer Berlin T (030) 362 06 - 390 F (030) 362 06 - 100 [email protected] HAVELKLINIK GMBH & CO. KG Gatower Straße 191 13595 Berlin-Spandau 10/2003 – 11/2008 Facharztausbildung an der Klinik für Dermatologie, Venerologie und Allergologie, Charité Universitätsmedizin. Klinikdirektor: Professor Dr. W. Sterry 07/1999 – 08/2001 Ärztin im Praktikum und im Anschluss Assistenzärztin an der Klinik und Poliklinik für Visceral- und Gefäßchirurgie der Universität zu Köln. Klinikdirektor: Professor Dr. A.H. Hölscher. Arbeitsbereich: Allgemeinchirurgische Intensivstation, Gefäßchirurgie 12/2000 Approbation als Ärztin. MANUSKRIPTE Wolk K, Wenzel J, Tsaousi A, Witte-Händel E, Babel N, Zelenak C, Volk HD, Sterry W, Schneider-Burrus S, Sabat R.Lipocalin-2 is expressed by activated granulocytes and keratinocytes in affected skin and reflects disease activity in acne inversa / hidradenitis suppurativa. Br J Dermatol. 2017 Mar 3. doi: 10.1111/bjd.15424 Tsaousi A, Witte E, Witte K, Röwert-Huber HJ, Volk HD, Sterry W, Wolk K, Schneider-Burrus S, Sabat R. MMP8 is increased in lesions and blood of acne inversa patients: a potential link to skin destruction and metabolic alterations. Mediators Inflamm. 2016;2016:4097574. Epub 2016 Oct 23. Sylke Schneider-Burrus, Ellen Witte, Demetrios Christou, Benedetta Rigoni, Robert Sabat, Gerd Diederichs. High prevalence of back pain and axial spondyloarthropathy in patients with hidradenitis suppurativa, Dermatology. 2016;232(5):606-612. Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhász I, Lapins J, Matusiak L, Prens EP, Revuz J, Schneider-Burrus S, Szepietowski JC, van der Zee HH, Jemec GB. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015 Apr;29(4):619-44 Kurek A, Peters E, Sabat R, Sterry W, Schneider-Burrus S. Depression is a frequent co-morbidity in patients with acne inversa. J Dtsch Dermatol Ges 2013 Aug;11(8):743-9. (IF 1,403) Sabat R, Chanwangpong A, Schneider-Burrus S, Metternich D, Kokolakis G, Kurek A, Philipp S, Uribe D, Wolk K, Sterry W. Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS One. 2012;7(2):e31810. Epub 2012 Feb 16. (IF 4,092) Kurek A, Chanwangpong A, Sabat R, Peters E, Sterry W, Schneider-Burrus S. Profound disturbances of sexual health in patients with Acne inversa. J Am Acad Dermatol. 2012 Sep;67(3):422-8 (IF 3,991) Wolk K, Warszawska K, Hoeflich C, Witte E, Schneider-Burrus S, Witte K, Kunz S, Buss A, Roewert HJ, Krause M, Lukowsky A, Volk HD, Sterry W, Sabat R. Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J Immunol. 2011 Jan 15;186(2):1228-39. (IF 5,788) Lukowsky A, Sterry W, Schneider-Burrus S. Prevalence of the MspI and Ile462Val SNPs of cytochrome P-450 1A1 in hidradenitis suppurativa. Exp Dermatol. 2010 Jun;19(6):541-2. (IF 4,159) Schneider-Burrus S, Drecoll U, Schlag PM. Operative Therapie des malignen Melanoms. Der Onkologe, 2009, Volume 15, Number 8, 750-757. (IF 0,157) Kuramochi H, Uchida K, Peters JH, Shimizu D, Vallbohmer D, Schneider S, Danenberg KD, Danenberg PV. Loss of heterozygosity at thymidylate synthase locus in Barrett's metaplasia, dysplasia, and carcinoma sequences. BMC Cancer. 2009 May 21;9:157. (IF 2,736) Schneider-Burrus S, Meixner D, Sterry W, Luckowsky A. Common NOD2 mutations are rare in patients with inverse acne. J Dermatol Sci. 2008 Oct;52(1):55-7. (IF 2,973) Meixner D, Schneider S, Krause M, Sterry W. Acne inversa. A review. J Dtsch Dermatol Ges. 2008 Mar;6(3):189-96. Yang D, Schneider S, Azuma M, Iqbal S, El-Khoueiry A, Groshen S, Agafitei D, Danenberg KD, Danenberg PV, Ladner RD, Lenz HJ. Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer. Clin Colorectal Cancer. 2006 Nov;6(4):305-11. Maza S, Taupitz M, Taymoorian K, Winzer KJ, Ruckert J, Paschen C, Raber G, Schneider S, Trefzer U, Munz DL. Multimodal fusion imaging ensemble for targeted sentinel lymph node management: initial results of an innovative promising approach for anatomically difficult lymphatic drainage in different tumour entities. Eur J Nucl Med Mol Imaging. 2007 Mar;34(3):378-83. (IF 4,101) Schneider S, Park D, Yang D, El-Khoueiry A, Sherrod A, Groshen S, Streeter O, Iqbal S, Danenberg K, and Lenz HJ. Gene association in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation. Pharmacogenet Genomics. 2006 Aug;16(8):555-63. (IF 5,391) Schneider S, Garcia Bartels C, Maza S, and Sterry W. Detection of Micrometastasis in a Sentinel Lymph Node of a Patient with Malignant Blue Nevus: A Case Report. Dermatol Surg. 2006 Aug;32(8):1089-92. (IF 2,309) Dang C, Gottschling M, Manning K, O´Currain E, Schneider S, Sterry W, Stockfleth E and Nindl I. Identification of dysregulated genes in cutaneous squamous cell carcinoma, Oncol Rep, 2006 Sep;16(3):513-9. (IF 1,567) Shimizu D, Vallbohmer D, Kuramochi H, Uchida K, Schneider S, Chandrasoma PT, Shimada H, Demeester TR, Danenberg KD, Peters JH, Demeester SR, Danenberg PV. Increasing cyclooxygenase-2 (cox-2) gene expression in the progression of Barrett's esophagus to adenocarcinoma correlates with that of Bcl-2. Int J Cancer. 2006 Aug 15;119(4):765-70. (IF 4,693) Maza S, Trefzer U, Hofmann M, Schneider S, Voit C, Krossin T, Zander A, Audring H, Sterry W, Munz DL. Impact of sentinel lymph node biopsy in patients with Merkel cell carcinoma: results of a prospective study and review of the literature. Eur J Nucl Med Mol Imaging. 2006 Apr;33(4):433-40. (IF 4,041) Gordon MA, Gil J, Lu B, Zhang W, Yang D, Yun J, Schneider S, Groshen S, Iqbal S, Press OA, Rhodes K, Lenz HJ. Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics. 2006 Jan;7(1):67-88. (IF 3,603 Uchida K, Schneider S, Yochim JM, Kuramochi H, Hayashi K, Takasaki K, Yang D, Danenberg KD, Danenberg PV. Related Articles, Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy. Clin Cancer Res. 2005 May 1;11(9):3363-8. (IF 5,715) Schneider S, Uchida K, Brabender J, Baldus SE, Yochim J, Danenberg KD, Salonga D, Chen P, Tsao-Wei D, Groshen S, Hoelscher AH, Schneider PM, Danenberg PV. Related Articles, Downregulation of TS, DPD, ERCC1, GSTPi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. J Am Coll Surg. 2005 Mar;200(3):336-44. (IF 2,621) Kuramochi H, Vallbohmer D, Uchida K, Schneider S, Hamoui N, Shimizu D, Chandrasoma PT, DeMeester TR, Danenberg KD, Danenberg PV, Peters JH. Related Articles, Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett's adenocarcinoma. J Gastrointest Surg. 2004 Dec;8(8):1007-16. Hamoui N, Peters JH, Schneider S, Uchida K, Yang D, Vallbohmer D, Hagen JA, DeMeester SR, DeMeester TR, Danenberg K, Danenberg P. Related Articles, Increased acid exposure in patients with gastroesophageal reflux disease influences cyclooxygenase-2 gene expression in the squamous epithelium of the lower esophagus. Arch Surg. 2004 Jul;139(7):712-6. (IF 3,076) Lu B, Mu Y, Cao C, Zeng F, Schneider S, Tan J, Price J, Chen J, Freeman M, Hallahan DE. Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res. 2004 Apr 15;64(8):2840-5. (IF 7,69) Brabender J, Marjoram P, Salonga D, Metzger R, Schneider PM, Park JM, Schneider S, Holscher AH, Yin J, Meltzer SJ, Danenberg KD, Danenberg PV, Lord RV. Related Articles, A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus. Oncogene. 2004 Jun 10;23(27):4780-8. (IF 6,318) Schneider S, Yochim J, Brabender J, Uchida K, Danenberg KD, Metzger R, Schneider PM, Salonga D, Holscher AH, Danenberg PV. Related Articles, Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin Cancer Res. 2004 Mar 1;10(5):1588-96. (IF 5,623) Uchida K, Hayashi K, Kawakami K, Schneider S, Yochim JM, Kuramochi H, Takasaki K, Danenberg KD, Danenberg PV. Related Articles, Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. Clin Cancer Res. 2004 Jan 15;10(2):433- (IF 5,623) Schneider S, Uchida K, Salonga D, Yochim JM, Danenberg KD, Danenberg PV. Quantitative determination of p16 gene expression by RT-PCR. Methods Mol Biol. 2004;281:91-103. Schneider S, Stöhlmacher J and Lenz H-J, Pharmakogenetik in kolorektalen Karzinomen, Der Onkologe 2003, Aug, Volume 9, Number 8 Brabender J, Usadel H, Metzger R, Schneider PM, Park J, Salonga D, Tsao-Wei DD, Groshen S, Lord RV, Takebe N, Schneider S, Holscher AH, Danenberg KD, Danenberg PV. Related Articles, Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin Cancer Res. 2003 Jan;9(1):223-7.